Robert J Anderson1, Gideon D Bahn2, Nicholas V Emanuele3, Jennifer B Marks4, William C Duckworth5. 1. Endocrinology, Veterans Affairs Medical Center, Omaha, NE robert.anderson4@va.gov. 2. Cooperative Studies Program Coordinating Center, Hines Veterans Affairs Hospital, Hines, IL. 3. Research and Medical Services, Hines Veterans Affairs Hospital, Hines, IL. 4. Medical Service, Endocrinology Section, Veterans Affairs Medical Center, Miami, FL. 5. Research Service, Veterans Affairs Medical Center, Phoenix, AZ.
Abstract
OBJECTIVE:Blood pressure (BP) control for renal protection is essential for patients with type 2 diabetes. Our objective in this analysis of Veterans Affairs Diabetes Trial (VADT) data was to learn whether on-study systolic BP (SBP), diastolic BP (DBP), and pulse pressure (PP) affected renal outcomes measured as albumin-to-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR). RESEARCH DESIGN AND METHODS: The VADT was a prospective, randomized study of 1,791 veterans with type 2 diabetes to determine whether intensive glucose control prevented major cardiovascular events. In this post hoc study, time-varying covariate survival analyses and hazard ratios (HR) were used to determine worsening of renal outcomes. RESULTS: Compared with SBP 105-129 mmHg, the risk of ACR worsening increased significantly for SBP 130-139 mmHg (HR 1.88 [95% CI 1.28-2.77]; P = 0.001) and for SBP≥140 mmHg (2.51 [1.66-3.78]; P < 0.0001). Compared with a PP range of 40-49 mmHg, PP <40 was associated with significantly lowered risk of worsening ACR (0.36 [0.15-0.87]; P = 0.022) and PP ≥60 with significantly increased risk (2.38 [1.58-3.59]; P < 0.0001). Analyses of BP ranges associated with eGFR worsening showed significantly increased risk with rising baseline SBP and an interaction effect between SBP≥140 mmHg and on-study A1C. These patients were 15% more likely than those with SBP <140 mmHg to experience eGFR worsening (1.15 [1.00-1.32]; P = 0.045) for each 1% (10.9 mmol/mol) A1C increase. CONCLUSIONS:SBP≥130 mmHg and PP >60 mmHg were associated with worsening ACR. The results suggest that treatment of SBP to <130 mmHg may lessen ACR worsening. The interaction between SBP≥140 mmHg and A1C suggests that the effect of glycemic control on reducing progression of renal disease may be greater in hypertensive patients.
RCT Entities:
OBJECTIVE: Blood pressure (BP) control for renal protection is essential for patients with type 2 diabetes. Our objective in this analysis of Veterans Affairs Diabetes Trial (VADT) data was to learn whether on-study systolic BP (SBP), diastolic BP (DBP), and pulse pressure (PP) affected renal outcomes measured as albumin-to-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR). RESEARCH DESIGN AND METHODS: The VADT was a prospective, randomized study of 1,791 veterans with type 2 diabetes to determine whether intensive glucose control prevented major cardiovascular events. In this post hoc study, time-varying covariate survival analyses and hazard ratios (HR) were used to determine worsening of renal outcomes. RESULTS: Compared with SBP 105-129 mmHg, the risk of ACR worsening increased significantly for SBP 130-139 mmHg (HR 1.88 [95% CI 1.28-2.77]; P = 0.001) and for SBP ≥140 mmHg (2.51 [1.66-3.78]; P < 0.0001). Compared with a PP range of 40-49 mmHg, PP <40 was associated with significantly lowered risk of worsening ACR (0.36 [0.15-0.87]; P = 0.022) and PP ≥60 with significantly increased risk (2.38 [1.58-3.59]; P < 0.0001). Analyses of BP ranges associated with eGFR worsening showed significantly increased risk with rising baseline SBP and an interaction effect between SBP ≥140 mmHg and on-study A1C. These patients were 15% more likely than those with SBP <140 mmHg to experience eGFR worsening (1.15 [1.00-1.32]; P = 0.045) for each 1% (10.9 mmol/mol) A1C increase. CONCLUSIONS: SBP ≥130 mmHg and PP >60 mmHg were associated with worsening ACR. The results suggest that treatment of SBP to <130 mmHg may lessen ACR worsening. The interaction between SBP ≥140 mmHg and A1C suggests that the effect of glycemic control on reducing progression of renal disease may be greater in hypertensivepatients.
Authors: Katja van den Hurk; Dianna J Magliano; Marjan Alssema; Markus P Schlaich; Robert C Atkins; Anne T Reutens; Giel Nijpels; Jacqueline M Dekker; Jonathan E Shaw Journal: J Hypertens Date: 2011-05 Impact factor: 4.844
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang Journal: N Engl J Med Date: 2008-12-17 Impact factor: 91.245
Authors: Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf Journal: Lancet Date: 2008-08-16 Impact factor: 79.321
Authors: Bastiaan E de Galan; Vlado Perkovic; Toshiharu Ninomiya; Avinesh Pillai; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Stephen Harrap; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Paul Glasziou; Diederick E Grobbee; Stephen MacMahon; John Chalmers Journal: J Am Soc Nephrol Date: 2009-02-18 Impact factor: 10.121
Authors: Robert J Anderson; Gideon D Bahn; Thomas E Moritz; Derrick Kaufman; Carlos Abraira; William Duckworth Journal: Diabetes Care Date: 2010-11-08 Impact factor: 19.112
Authors: Sophia Zoungas; Bastiaan E de Galan; Toshiharu Ninomiya; Diederick Grobbee; Pavel Hamet; Simon Heller; Stephen MacMahon; Michel Marre; Bruce Neal; Anushka Patel; Mark Woodward; John Chalmers; Alan Cass; Paul Glasziou; Stephen Harrap; Liu Lisheng; Guiseppe Mancia; Avinesh Pillai; Neil Poulter; Vlado Perkovic; Florence Travert Journal: Diabetes Care Date: 2009-08-03 Impact factor: 19.112
Authors: Marinella Ruospo; Valeria M Saglimbene; Suetonia C Palmer; Salvatore De Cosmo; Antonio Pacilli; Olga Lamacchia; Mauro Cignarelli; Paola Fioretto; Mariacristina Vecchio; Jonathan C Craig; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2017-06-08
Authors: Claudia R L Cardoso; Nathalie C Leite; Guilherme C Salles; Marcel T Ferreira; Gil F Salles Journal: Diabetologia Date: 2017-10-23 Impact factor: 10.122
Authors: Jong Ho Kim; Sang Soo Kim; In Joo Kim; Bo Hyun Kim; Ja Young Park; Chang Won Lee; Ji Hye Suk; Sun Hae Shin; Sung Pyo Son; Min Chul Kim; Jun Hyeob Ahn; Kwang Jae Lee; Min Jung Kwon; Soon Hee Lee; Jeong Hyun Park Journal: J Diabetes Res Date: 2017-08-16 Impact factor: 4.011
Authors: Allison A Lewinski; Uptal D Patel; Clarissa J Diamantidis; Megan Oakes; Khaula Baloch; Matthew J Crowley; Jonathan Wilson; Jane Pendergast; Holly Biola; L Ebony Boulware; Hayden B Bosworth Journal: J Med Internet Res Date: 2019-04-09 Impact factor: 5.428